CAP-100

Phase 1Small molecule

CCatapult Therapeutics

CAP-100 is one of 52 small molecule programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaRecruiting

Chronic Lymphocytic LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

94 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

38 2

Venclexta

AbbVie

Phase 3

51 3

Gazyva

Roche

Phase 3

59 4

Calquence

AstraZeneca

Phase 3

27 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

40 6

Brukinsa

BBeOne Medicines

Phase 3

17 7

Keytruda

Merck & Co.

Phase 3

2 8

Adcetris

Pfizer

Phase 3

1 9

Beqalzi

BBeOne Medicines

Phase 3

8 10

Campath

GGenzyme, a Sanofi Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Chronic Lymphocytic Leukemia

NCT04704323

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Recruiting·CCatapult Therapeutics·Phase 1·NCT04704323·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CAP-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAP-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAP-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Catapult Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCatapult Therapeutics

CAP-100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News